Gain insight into research trends and influential papers with Research Intelligence.
doi.org/10.1186/1546-0096-6-s1-s2

2.2 A phase II trial with canakinumab, a new IL-1beta blocking monoclonal antibody (ACZ885), to evaluate preliminary dosing, safety and efficacy profile in children with systemic Juvenile Idiopathic arthritis (sJIA)

..., C Rordorf
1
Pediatric Rheumatology2.50
Volume: 6, Issue: S1
Published: Sep 1, 2008
Abstract
Open Access Oral presentation 2.2 A phase II trial with canakinumab, a new IL-1beta blocking monoclonal antibody (ACZ885), to evaluate preliminary dosing, safety and efficacy profile in children with systemic Juvenile Idiopathic arthritis (sJIA) N Ruperto*1, P Quartier2, N Wulffraat3, P Woo4, A Loy1, R Mouy2, B BaderMeunier2, B Prakken3, E Noseda5, C Rordorf5 and Martini for the Paediatric Rheumatology International Trials Organisation (PRINTO)...
Paper Fields
Paper Details
Title
2.2 A phase II trial with canakinumab, a new IL-1beta blocking monoclonal antibody (ACZ885), to evaluate preliminary dosing, safety and efficacy profile in children with systemic Juvenile Idiopathic arthritis (sJIA)
DOI
doi.org/10.1186/1546-0096-6-s1-s2
Published Date
Sep 1, 2008
Journal
Pediatric Rheumatology
Volume
6
Issue
S1
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.